Literature DB >> 34267469

Myeloablative Versus Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis.

Sanjeev Kumar Sharma1, Dharma Choudhary1, Divya Doval1, Vipin Khandelwal1, Amee Patel1, Rasika Setia1, Tina Dadu1, Anil Handoo1.   

Abstract

The conditioning regimens used for the allo-HSCT include either myeloablative conditioning (MAC) or reduced intensity conditioning (RIC) regimens based on the age, performance status and co-morbidities. Studies comparing the survival outcomes of RIC and MAC allo-HSCT in AML and MDS patients have reported contradictory results. We therefore retrospectively analyzed our data of AML and MDS patients who received MAC and RIC allo-HSCT at our center and compared the long term outcome of the two conditioning regimens. One hundred twenty six consecutive patients were evaluated, 32 (25.4%) underwent MAC allo-HSCT and 94 (74.6%) underwent RIC allo-HSCT. The most common MAC regimen used was busulfan plus cyclophosphamide and the most common RIC regimen used was fludarabine plus melphalan. The median age was higher in RIC group (44 years, range 4-75 years) compared to MAC group (31 yrs, range 6-51 yrs, p = 0.001). There was no significant difference in terms of overall survival (p = 0.498), relapse-free survival (p = 0.791) and non-relapse mortality (p = 0.366) between the two groups. In multivariate analysis, only chronic graft-versus-host disease resulted in decreased risk of relapse and improved overall survival irrespective of the conditioning regimens used. © Indian Society of Hematology and Blood Transfusion 2020.

Entities:  

Keywords:  Allogeneic stem cell transplant; GVHD; Myeloablative conditioning; Overall survival; Reduced intensity conditioning

Year:  2020        PMID: 34267469      PMCID: PMC8239118          DOI: 10.1007/s12288-020-01386-6

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.915


  14 in total

1.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

2.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).

Authors:  M Aoudjhane; M Labopin; N C Gorin; A Shimoni; T Ruutu; H-J Kolb; F Frassoni; J M Boiron; J L Yin; J Finke; H Shouten; D Blaise; M Falda; A A Fauser; J Esteve; E Polge; S Slavin; D Niederwieser; A Nagler; V Rocha
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

Review 3.  Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia.

Authors:  Mitchell E Horwitz
Journal:  Curr Opin Oncol       Date:  2011-03       Impact factor: 3.645

4.  Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

Authors:  Nicolaus Kröger; Simona Iacobelli; Georg-Nikolaus Franke; Uwe Platzbecker; Ruzena Uddin; Kai Hübel; Christof Scheid; Thomas Weber; Marie Robin; Matthias Stelljes; Boris Afanasyev; Dominik Heim; Giorgio Lambertenghi Deliliers; Francesco Onida; Peter Dreger; Massimo Pini; Stefano Guidi; Liisa Volin; Andreas Günther; Wolfgang Bethge; Xavier Poiré; Guido Kobbe; Marleen van Os; Ronald Brand; Theo de Witte
Journal:  J Clin Oncol       Date:  2017-05-02       Impact factor: 44.544

5.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Bart L Scott; Marcelo C Pasquini; Brent R Logan; Juan Wu; Steven M Devine; David L Porter; Richard T Maziarz; Erica D Warlick; Hugo F Fernandez; Edwin P Alyea; Mehdi Hamadani; Asad Bashey; Sergio Giralt; Nancy L Geller; Eric Leifer; Jennifer Le-Rademacher; Adam M Mendizabal; Mary M Horowitz; H Joachim Deeg; Mitchell E Horwitz
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

6.  Defining the intensity of conditioning regimens: working definitions.

Authors:  Andrea Bacigalupo; Karen Ballen; Doug Rizzo; Sergio Giralt; Hillard Lazarus; Vincent Ho; Jane Apperley; Shimon Slavin; Marcelo Pasquini; Brenda M Sandmaier; John Barrett; Didier Blaise; Robert Lowski; Mary Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-01       Impact factor: 5.742

7.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.

Authors:  Hakan Goker; Evren Ozdemir; Burak Uz; Yahya Buyukasik; Mehmet Turgut; Songul Serefhanoglu; Salih Aksu; Nilgun Sayinalp; Ibrahim C Haznedaroglu; Fatma Tekin; Yasemin Karacan; Sevilay Unal; Eylem Eliacik; Ayse Isik; Osman I Ozcebe
Journal:  Transfus Apher Sci       Date:  2013-08-08       Impact factor: 1.764

8.  Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

Authors:  Martin Bornhäuser; Joachim Kienast; Rudolf Trenschel; Andreas Burchert; Ute Hegenbart; Michael Stadler; Herrad Baurmann; Kerstin Schäfer-Eckart; Ernst Holler; Nicolaus Kröger; Christoph Schmid; Herrmann Einsele; Michael G Kiehl; Wolfgang Hiddemann; Rainer Schwerdtfeger; Stefanie Buchholz; Peter Dreger; Andreas Neubauer; Wolfgang E Berdel; Gerhard Ehninger; Dietrich W Beelen; Johannes Schetelig; Matthias Stelljes
Journal:  Lancet Oncol       Date:  2012-09-07       Impact factor: 41.316

Review 9.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

Authors:  S Fadilah Abdul Wahid; Nor-Azimah Ismail; Mohd-Razif Mohd-Idris; Fariza Wan Jamaluddin; NorRafeah Tumian; Ernie Yap Sze-Wei; Norasiah Muhammad; Ming Lai Nai
Journal:  Stem Cells Dev       Date:  2014-09-17       Impact factor: 3.272

10.  Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India.

Authors:  Abhijeet Ganapule; Sandeep Nemani; Anu Korula; Kavitha M Lakshmi; Aby Abraham; Alok Srivastava; Poonkuzhali Balasubramanian; Biju George; Vikram Mathews
Journal:  J Glob Oncol       Date:  2017-02-08
View more
  1 in total

1.  Hematopoietic Stem Cell Transplant for Hematological Malignancies: Experience from a Tertiary Care Center in Northern India and Review of Indian Data.

Authors:  Sanjeev Kumar Sharma; Dharma Choudhary; Divya Doval; Vipin Khandelwal; Rasika Setia; Tina Dadu; Anil Handoo
Journal:  South Asian J Cancer       Date:  2021-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.